The average cost for a Big Pharma ... more intricate and complex research areas, macroeconomic factors, tech advancements and high attrition rates; the pharma cohort spent $7.7 billion on trials ...

Returns on pharma R&D investment are at a nine ... areas such as oncology and neurology were driving up costs and the length of development cycles. This was despite the efforts of regulators ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

It’s unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is hoping for, some experts said.

Biocon's Siddharth Mittal challenges the feasibility of relocating pharma manufacturing to the US from China and India.

In an era where healthcare advancements are at their peak, an often overlooked, yet critical, aspect is the management of pharmaceutical waste. This intricate balance of cost, compliance ...

Experts say any added costs would be passed onto the ... a major impact on consumers but could impact the research and development areas of pharmaceutical companies. He explained that ...